AstraZeneca PLC, AZN is in the exchange NYSE and its industry is Drug Manufacturers – Major in the sector of Healthcare. Based in United Kingdom, AstraZeneca PLC, AZN has a market cap of 77392.7. Since its IPO date on the 5/17/1993, AstraZeneca PLC, AZN performance year to date is -5.74%. Today AstraZeneca PLC, AZN has gained -0.81%, with a current price of 30.59.
Ownership of the company is 0.50% for insider ownership while institutional ownership is 12.20%. The management of the company have seen the company have a payout ratio of 108.10%. Return of assets are at 3.70%, with return on investment at 11.50%.
In terms of debt levels and profit levels, AstraZeneca PLC, AZN is seeing a long-term debt/equity of 1.22. While Total debt/equity is 1.3. With a profit margin of 9.20%, this is combined with a gross margin of 82.20%, and operating margin of 15.00%. AstraZeneca PLC ability to meet debt levels, with a current ratio of 0.9, while the quick ratio is 0.8.
For the last year AstraZeneca PLC, AZN has seen a EPS growth of 128.90%. A performance for the year of -0.74%. The 52-week high is -11.53%, and the 52-week low is 14.94%. The average volume for AstraZeneca PLC, AZN is 4252767.
With a target price of 36.09, can AstraZeneca PLC, AZN reach this target? Looking at the value indicators of AstraZeneca PLC, AZN. AstraZeneca PLC has a P/E of 34.84 and a forward P/E of 10.48. Perhaps the more useful indicator than P/E, is PEG which has a value of *TBA. AstraZeneca PLC also has a P/S and a P/B of 3.22 and 5.72 respectively. For P/cash, AstraZeneca PLC has a value of 16.66, while it is *TBA for P/free cash flow.
At the current price of 30.59, AstraZeneca PLC has a dividend yield of 2.94%. We see a return on equity of 13.90%.
Looking more long-term AstraZeneca PLC, is projected to get an EPS growth for the next five years of -1.00%. In the short-term an EPS growth of -11.86% in the next year is forecasted. This is after a EPS growth of 128.90% for this year and for the last five years a -16.70% growth has been seen.